Recipharm

Last updated
Recipharm AB
FormerlyRecip
IndustryPharmaceutical Contract Development and Manufacturing Organisation
Founded Stockholm, Sweden, 1995
Headquarters
Stockholm, Sweden
Key people
Richard Ridinger, Chairman, Greg Behar, CEO, Joaquim Mascaró, CFO
ProductsPharmaceutical products for humans
RevenueSEK 11,069 million (2020)
Number of employees
5,200 (2024)
Website recipharm.com

Recipharm is a leading global Contract Development and Manufacturing Organisation (CDMO), employing 5,200 people and operating in over a hundred markets worldwide.

Contents

Recipharm offers pharmaceutical manufacturing services across various dosage forms, including sterile fill & finish, oral solid dosage, and biologics. Additionally, they provide clinical trial material development and manufacturing services, as well as pharmaceutical product development.

Recipharm manufactures several hundred different products for customers ranging from large pharmaceutical companies to smaller research and development firms.

History

Recip 1995-2007

In March 1995, Thomas Eldered and Lars Backsell conducted a management buyout of a Pharmacia solid dose tablet manufacturing facility in Årsta, Stockholm and formed the company “Recip”. The facility had 130 employees and a turnover of SEK 220 million. [1] The company continued to manufacture pharmaceutical products for Pharmacia during a transition period while it also developed its own products. Recip also began providing contract manufacturing services to other pharmaceutical companies.

In 1997, Recip was believed to be the first pharmaceutical company in the world to certify its entire operations according to the ISO 14001 environmental management system. [2] From 1998, the company began to grow by acquiring facilities in Sweden. The brand name “Recipharm” was established in 2001 for the growing contract manufacturing part of Recip's business. In 2007, the Recip part of the business and the company's own portfolio were divested to Meda. [3]

Recipharm 2007-present

Following the sale of Recip, the company focused on its contract manufacturing business. The capital from the sale of Recip was used to make further acquisitions – initially in Europe and later the US and India. Acquisitions were used to broaden the company's offering and customer base, and to enter new markets.

Recipharm became a public listed company on Nasdaq Stockholm in 2014. [4] Between 2014 and 2019, Recipharm's sales grew by an average of more than 30 per cent annually, including a combination of internal growth and acquisitions.[ citation needed ] In 2020, Recipharm completed its largest acquisition to date. The £505 million takeover of UK-based Consort Medical added around 2,000 employees and ten European facilities to the company, as well as new device capabilities.

In February 2021, Private equity firm EQT acquired Recipharm [5] for $2.1 billion. In March 2021, Mark Funk joined Recipharm as CEO, replacing Thomas Eldered who remains on the board of directors. [5]

The Recipharm International Environmental Award

Recipharm's International Environmental Award is annually awarded for the best environmental performance or environmental innovation within the pharmaceutical industry or academia. [6]

External Recognition

Related Research Articles

<span class="mw-page-title-main">Pharmacia</span> Pharmaceutical and biotechnological company

Pharmacia was a pharmaceutical and biotechnological company in Sweden that merged with the American pharmaceutical company Upjohn in 1995.

<span class="mw-page-title-main">Investor AB</span> Swedish investment and conglomerate holding company

Investor AB is a Swedish investment and holding company, often considered a de facto conglomerate. One of Sweden's largest companies, Investor AB serves as the investment arm of the prominent Swedish Wallenberg family; the family's companies are involved in a variety of industries, of which the primary industries are pharmaceuticals, telecommunications and industry.

<span class="mw-page-title-main">Atlas Copco</span> Swedish multinational industrial company

Atlas Copco is a Swedish multinational industrial company that was founded in 1873. It manufactures industrial tools and equipment.

Aptalis was a company in the pharmaceutical industry. In January 2014, the company was acquired by Forest Laboratories for $675 million. Through a series of acquisitions, the company is now a contract development and manufacturing organization and rebranded as Adare Phama Solutions, headquartered in Lawrenceville, New Jersey.

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

Hexagon AB is a multinational industrial technology company. Headquartered in Stockholm, Sweden and publicly traded on the Nasdaq Stockholm exchange, the company since 2000 has had a particular focus on measuring technology and geospatial tools and software. After its founding, between 2000 and 2022, Hexagon completed more than 170 acquisitions, and it is the parent company of Leica Geosystems and Infor EAM, among other subsidiaries. With around 24,000 employees, Hexagon's revenue in 2023 was US$5.5 billion, while assets were $18.1 billion.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. The company publishes the annual Parexel R&D Statistical Sourcebook and operates the Parexel-Academy.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

<span class="mw-page-title-main">Cambrex Corporation</span> American pharmaceutical company

Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets for API and dosage form development and manufacturing.

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

<span class="mw-page-title-main">Novozymes</span> Danish Biotechnology Company

Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

<span class="mw-page-title-main">Swedish Orphan Biovitrum</span> Swedish pharmaceutical company

Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

<span class="mw-page-title-main">Dechra Pharmaceuticals</span> Pharmaceutical Company based in UK

Dechra is a business involved in the development and marketing of veterinary products based in Northwich, England. It was listed on the London Stock Exchange until it was acquired by EQT AB in January 2024.

<span class="mw-page-title-main">BTS Group</span> BTS group

BTS Group AB (BTS) is a strategic consulting firm founded in 1986. The company serves banking, biotech and pharmaceutical, consumer products, insurance, manufacturing, oil and gas, professional services, retail, technology, and telecommunications sectors.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

Curia is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. Curia has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Company, Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

References

  1. "The Recipharm story". Recipharm. Archived from the original on 2016-08-16. Retrieved 17 March 2017 via Internet Archive.
  2. Nyström, Anna (2 May 2005). "Läkemedelsföretag med miljöprofil" [Pharmaceutical company with an environmental profile]. Miljö & Utveckling (in Swedish). Retrieved 10 September 2022.
  3. "Meda acquires Recip" (PDF) (Press release). Meda AB. Retrieved 10 September 2022.
  4. "Recipharm". Recipharm. 2014. Retrieved 17 March 2020 via NASDAQ.
  5. 1 2 "Recipharm". Current Portfolio. EQT. 2021. Retrieved 10 September 2022.
  6. "Recipharm International Environmental Award".
  7. "Lars Backsell och Thomas Eldered, Recipharm, från Jordbro är två av Sveriges främsta entreprenörer". News Powered by Cision (in Swedish). Retrieved 2020-03-17.
  8. "Founders of Recipharm awarded enterprise medal". Nordic Life Science – the leading Nordic life science news service. 2014-04-11. Retrieved 2020-03-17.
  9. "Recipharm AB: Recipharm wins SwedenBIO Award - Analysguiden". Aktiespararna (in Swedish). 5 June 2015. Retrieved 2020-03-17.